Sanyou Biopharmaceutical, a biopharmaceutical company and Guangzhou Baiyunshan Xihe Health Pharmaceutical jointly announced the official signing of a cooperation agreement. This partnership will focus on the co-development of novel radiopharmaceuticals and radiodiagnostic products, aiming to integrate their respective core strengths in AI-driven innovative drug molecule discovery and the full industrial value chain of nuclear medicine. Together, the two parties seek to build an end-to-end innovation chain spanning from target molecule discovery to clinical translation of radiopharmaceuticals, delivering more transformative solutions for precision oncology diagnosis and therapy.

The development of radiopharmaceuticals and radiodiagnostic products places extremely high demands on the precision, stability and druggability of targeting molecules. This strategic collaboration is based on both parties' deep insight into the nuclear medicine industry trends and strong mutual recognition of each other's technological capabilities.

Sanyou Bio will leverage its globally leading AI-Super trillion antibody/molecule libraries (AI-STAL) and its Sanyou AI-Drug Accelerator (SAI-DA) to provide source innovation power for the discovery and optimisation of high-performance antibodies and targeting molecules against specific targets. Baiyunshan Xihe will rely on its end-to-end capabilities in novel medical radionuclide production, GMP manufacturing and clinical translation to advance partnered molecules into radiolabelling, in vitro and in vivo evaluation, and preclinical studies, thereby accelerating the industrialisation of innovative radiopharmaceuticals and radiodiagnostic products.

The strategic partnership aims to create long-term value by integrating expertise across research, development and commercialisation. As part of the collaboration, the two companies will establish an end-to-end innovation ecosystem that combines AI-driven molecular discovery, radionuclide labelling and clinical translation into a unified research and development model. 

This integrated approach is expected to streamline the drug development process, significantly reducing the time required to advance from target identification to radiopharmaceutical candidate compounds. The partners will also work together to develop a differentiated portfolio of theranostic radiopharmaceuticals and novel radiodiagnostic products by combining Sanyou Bio's expertise in innovative drug development and AI-powered molecular discovery with Baiyunshan Xihe's standardized production technologies for key medical radionuclides, including Gallium-68, Zirconium-89, Copper-64 and Rhenium-186. 

Additionally, the collaboration seeks to establish a new industrial ecosystem by leveraging the companies' combined strengths in innovative drug R&D services and the nuclear medicine value chain. Through an open and collaborative model, the partnership aims to strengthen China's radiopharmaceutical innovation capabilities and support the high-quality development of the country's nuclear medicine industry.

Liu Hong, Chairman and General Manager, Baiyunshan Xihe, stated, "We are very pleased to enter into this strategic collaboration with Sanyou Bio. As a leading enterprise in Guangzhou's nuclear medicine industry chain, Baiyunshan Xihe has established a fully integrated value chain from radionuclide production to clinical services, and has developed a dual-track product portfolio featuring both self-developed nanobody-based RDCs and mature microsphere products. Sanyou Bio's AI-STAL platform for upstream drug discovery is globally leading, with a library capacity exceeding 11 trillion and outstanding screening capabilities. This collaboration will strongly complement our capabilities in targeting molecule discovery and accelerate the layout and advancement of our theranostic radiopharmaceutical pipeline. We look forward to this deep integration of 'discovery plus translation' to jointly develop truly clinically valuable innovative radiopharmaceutical products."

Dr Lang Guojun, founder and CEO of Sanyou Bio, stated, "This collaboration with Baiyunshan Xihe represents an important extension of Sanyou Bio's mission—'To make it easy to develop new drugs worldwide'—into the cutting-edge field of nuclear medicine. Backed by the strong industrial resources of Guangzhou Pharmaceutical Holdings, Baiyunshan Xihe has built solid capabilities in radionuclide production and full value-chain integration. This strategic synergy is a key step in deeply connecting our AI-driven molecular discovery capabilities with a leading radiopharmaceutical industrialization platform. We believe that, through the dual engines of 'intelligent molecular design' and 'precise radionuclide labelling,' we can provide truly fundamental solutions to upstream innovation challenges in nuclear medicine, jointly empowering the technological upgrade of the global nuclear medicine industry."

This strategic collaboration marks a solid step forward for Sanyou Bio in deepening industrial synergy and expanding into cutting-edge application areas. Starting from this partnership, both parties will continue to explore broader collaboration opportunities and strive to become a benchmark force driving upstream innovation in radiopharmaceutical development in China.

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of ‘To make it easy to develop new drugs worldwide’. The company is committed to fundamentally addressing the key challenges at the source of innovative drug development.